Ghent University Academic Bibliography

Your filters: cql: author="Larsson, Erik" or (type any "bookEditor issueEditor" and editor="Larsson, Erik")

Add to list
- Journal Article
- A1
- open access
A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues

Tom Luijts (UGent) , Kerryn Elliott, Joachim Siaw (UGent) , Joris Van de Velde (UGent) , Elien Beyls (UGent) , Arne Claeys (UGent) , Tim Lammens (UGent) , Erik Larsson, Wouter Willaert (UGent) , Anne Vral (UGent) , et al.

(2022) SCIENTIFIC REPORTS. 12.
Add to list
- Journal Article
- A1
- open access
Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis

Joana Carlevaro-Fita, Andres Lanzos, Lars Feuerbach, Chen Hong, David Mas-Ponte, Jakob Skou Pedersen, Rory Johnson, Federico Abascal, Samirkumar B. Amin, Gary D. Bader, et al.

(2020) COMMUNICATIONS BIOLOGY. 3(1).
Add to list
- Journal Article
- A1
- open access
Pan-cancer analysis of whole genomes

Peter J. Campbell, Gad Getz, Jan O. Korbel, Joshua M. Stuart, Jennifer L. Jennings, Lincoln D. Stein, Marc D. Perry, Hardeep K. Nahal-Bose, B. F. Francis Ouellette, Constance H. Li, et al.

(2020) NATURE. 578(7793). p.82-93
Add to list
Lack of detectable neoantigen depletion signals in the untreated cancer genome

Jimmy Van den Eynden (UGent) , Alejandro Jiménez-Sánchez, Martin L Miller and Erik Larsson

(2019) NATURE GENETICS. 51(12). p.1741-1748
Add to list
Targeting filamin A reduces macrophage activity and atherosclerosis

Sashidar Bandaru, Chandu Ala, Reza Salimi, Murali K Akula, Matias Ekstrand, Sravani Devarakonda, Joakim Karlsson, Jimmy Van den Eynden (UGent) , Goran Bergström, Erik Larsson, et al.

(2019) CIRCULATION. 140(1). p.67-79
Add to list
- Journal Article
- A1
Elevated pyrimidine dimer formation at distinct genomic bases underlies promoter mutation hotspots in UV-exposed cancers

Kerryn Elliott, Martin Boström, Stefan Filges, Markus Lindberg, Jimmy Van den Eynden (UGent) , Anders Ståhlberg, Anders R Clausen and Erik Larsson

(2018) PLOS GENETICS. 14(12).
Add to list
- Journal Article
- A1
An antisense RNA capable of modulating the expression of the tumor suppressor microRNA-34a

Jason T Serviss, Nathanael Andrews, Jimmy Van den Eynden (UGent) , Felix Clemens Richter, Miranda Houtman, Mattias Vesterlund, Laura Schwarzmueller, Per Johnsson, Erik Larsson, Dan Grandér, et al.

(2018) CELL DEATH & DISEASE. 9(7).
Add to list
Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways

Jimmy Van den Eynden (UGent) , Ganesh Umapathy, Arghavan Ashouri, Diana Cervantes-Madrid, Joanna Szydzik, Kristina Ruuth, Jan Koster, Erik Larsson, Jikui Guan, Ruth H Palmer, et al.

(2018) SCIENCE SIGNALING. 11(557).
Add to list
- Journal Article
- A2
Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib

Jikui Guan, Susanne Fransson, Joachim Tetteh Siaw, Diana Treis, Jimmy Van den Eynden (UGent) , Damini Chand, Ganesh Umapathy, Kristina Ruuth, Petter Svenberg, Sandra Wessman, et al.

(2018) COLD SPRING HARBOR MOLECULAR CASE STUDIES. 4(4).
Add to list
- Journal Article
- A1
Mutational signatures are critical for proper estimation of purifying selection pressures in cancer somatic mutation data when using the dN/dS metric

Jimmy Van den Eynden (UGent) and Erik Larsson

(2017) FRONTIERS IN GENETICS. 8.

Academic Bibliography

A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues

Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis

Pan-cancer analysis of whole genomes

Lack of detectable neoantigen depletion signals in the untreated cancer genome

Targeting filamin A reduces macrophage activity and atherosclerosis

Elevated pyrimidine dimer formation at distinct genomic bases underlies promoter mutation hotspots in UV-exposed cancers

An antisense RNA capable of modulating the expression of the tumor suppressor microRNA-34a

Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib

Mutational signatures are critical for proper estimation of purifying selection pressures in cancer somatic mutation data when using the dN/dS metric

Contents

Support

Contact